MHTX (Manhattan Scientifics) Additional Paid-In Capital: $69.00 Mil(As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Manhattan Scientifics Additional Paid-In Capital?

Manhattan Scientifics MHTX -90.00% Additional Paid-In Capital is $69.00 Mil as of Jun. 2024.


Manhattan Scientifics's quarterly additional paid-in capital stayed the same from Dec. 2023 ($69.00 Mil) to Mar. 2024 ($69.00 Mil) and stayed the same from Mar. 2024 ($69.00 Mil) to Jun. 2024 ($69.00 Mil).

Manhattan Scientifics's annual additional paid-in capital stayed the same from Dec. 2021 ($69.00 Mil) to Dec. 2022 ($69.00 Mil) and stayed the same from Dec. 2022 ($69.00 Mil) to Dec. 2023 ($69.00 Mil).

Manhattan Scientifics Additional Paid-In Capital Related Terms

Manhattan Scientifics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Manhattan Scientifics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Manhattan Scientifics Additional Paid-In Capital Chart

Manhattan Scientifics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.63 69.00 69.00 69.00 69.00

Manhattan Scientifics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.00 69.00 69.00 69.00 69.00

Manhattan Scientifics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $69.00 Mil mean?
Manhattan Scientifics (MHTX) has a Additional Paid-In Capital of $69.00 Mil as of Jun. 2024. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Manhattan Scientifics and its competitors.
Is Manhattan Scientifics' Additional Paid-In Capital too high?
Manhattan Scientifics' current Additional Paid-In Capital is $69.00 Mil.
How does Manhattan Scientifics' Additional Paid-In Capital compare to TBIO and CUTRQ?
Manhattan Scientifics' Additional Paid-In Capital of $69.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Medical Devices & Instruments company?
A good Additional Paid-In Capital depends on the Medical Devices & Instruments industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Manhattan Scientifics and its competitors. Manhattan Scientifics's current Additional Paid-In Capital is $69.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Manhattan Scientifics stock overvalued right now?
Manhattan Scientifics (MHTX) has a current Additional Paid-In Capital of $69.00 Mil. The current Additional Paid-In Capital is $69.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Manhattan Scientifics (MHTX), the current Additional Paid-In Capital is $69.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Manhattan Scientifics Business Description

Address 244 Fifth Avenue, Suite 2341, New York, NY, USA, 10001
Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. Its current focus is on the development of nanomaterials through the acquisition of Metallicum.